The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study

[1]  A. Lazzarin,et al.  The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study , 2014, Retrovirology.

[2]  M. Humbert,et al.  Novel Biopanning Strategy To Identify Epitopes Associated with Vaccine Protection , 2013, Journal of Virology.

[3]  R. Rappuoli,et al.  HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies , 2012, PloS one.

[4]  A. Lazzarin,et al.  Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART , 2010, PloS one.

[5]  D. O’Connor,et al.  Impact of Viral Dose and Major Histocompatibility Complex Class IB Haplotype on Viral Outcome in Mauritian Cynomolgus Monkeys Vaccinated with Tat upon Challenge with Simian/Human Immunodeficiency Virus SHIV89.6P , 2010, Journal of Virology.

[6]  S. Arold,et al.  Phosphatidylinositol‐(4,5)‐bisphosphate enables efficient secretion of HIV‐1 Tat by infected T‐cells , 2010, The EMBO journal.

[7]  Susan Engelbrecht,et al.  Functions of Tat: the versatile protein of human immunodeficiency virus type 1. , 2010, The Journal of general virology.

[8]  M. Giacca,et al.  Immobilized HIV‐1 Tat protein promotes gene transfer via a transactivation‐independent mechanism which requires binding of Tat to viral particles , 2009, The journal of gene medicine.

[9]  M. Magnani,et al.  HIV-1 Tat Addresses Dendritic Cells to Induce a Predominant Th1-Type Adaptive Immune Response That Appears Prevalent in the Asymptomatic Stage of Infection , 2009 .

[10]  P. Narciso,et al.  The therapeutic phase I trial of the recombinant native HIV-1 Tat protein , 2008, AIDS.

[11]  D. Montefiori,et al.  A Replication-Competent Adenovirus-Human Immunodeficiency Virus (Ad-HIV) tat and Ad-HIV env Priming/Tat and Envelope Protein Boosting Regimen Elicits Enhanced Protective Efficacy against Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques , 2007, Journal of Virology.

[12]  M. Ciccozzi,et al.  The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. , 2005, The Journal of infectious diseases.

[13]  K. Khalili,et al.  Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. , 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  Yuntao Wu,et al.  Selective Transcription and Modulation of Resting T Cell Activity by Preintegrated HIV DNA , 2001, Science.

[15]  M. Re,et al.  Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  F. Mueller,et al.  Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma. , 2000, Journal of human virology.

[17]  W. Blattner,et al.  Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. , 1998, Journal of human virology.

[18]  Luigi Buonaguro,et al.  HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.

[19]  A. Pardee,et al.  Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Moore,et al.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 , 1997, Journal of virology.

[21]  C. Van Lint,et al.  Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway , 1997, Science.

[22]  M. Raffeld,et al.  Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma , 1994, Nature.

[23]  P. Wingfield,et al.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.

[24]  S. Salahuddin,et al.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients , 1990, Nature.

[25]  C. Debouck,et al.  Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV‐1 , 1990, Journal of medical virology.

[26]  C. Debouck,et al.  Natural antibodies to HIV‐tat epitopes and expression of HIV‐1 genes in vivo , 1988, Journal of medical virology.